| アブストラクト | Clozapine is a cornerstone treatment for schizophrenia, though long-term use has been associated with significant adverse effects, including hematologic risks. This study analyzed FDA Adverse Event Reporting System (FAERS) data from 2003 to 2024 to assess the potential link between clozapine and lymphoma. Disproportionality analyses revealed elevated reporting odds ratios (RORs) for clozapine: Hodgkin lymphoma (HL) (3.76; 95% CI: 2.84-4.97) and non-Hodgkin lymphoma (NHL) (3.62; 95% CI: 2.88-4.54), while other antipsychotics showed no significant associations. Although causality cannot be established, the results underscore the need for targeted research into clozapine-associated risks and improved monitoring strategies to protect patients reliant on this medication. Further studies are essential to refine safety protocols and understand population-specific risks. |
|---|
| ジャーナル名 | Leukemia & lymphoma |
|---|
| Pubmed追加日 | 2025/2/12 |
|---|
| 投稿者 | Frey, Connor; Etminan, Mahyar |
|---|
| 組織名 | Department of Medicine, University of British Columbia, Vancouver, British;Columbia, Canada.;Department of Ophthalmology and Visual Sciences, University of British Columbia,;Vancouver, British Columbia, Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39937100/ |
|---|
